WO2010072327A3 - Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch - Google Patents
Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch Download PDFInfo
- Publication number
- WO2010072327A3 WO2010072327A3 PCT/EP2009/008768 EP2009008768W WO2010072327A3 WO 2010072327 A3 WO2010072327 A3 WO 2010072327A3 EP 2009008768 W EP2009008768 W EP 2009008768W WO 2010072327 A3 WO2010072327 A3 WO 2010072327A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibiting
- treated
- diseases
- zaap
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Die Erfindung betrifft Peptide, die z.B. aus Kamelmilch isolierbar sind, und als Wirkstoff in pharmazeutischen Zusammensetzungen verwendet werden können, insbesondere zur Verwendung bei medizinischen Indikationen, die durch Hemmung der humanen DPP4, CD26, zAAP und/oder DPP8 und/oder DPP9 therapiert werden können, insbesondere Diabetes mellitus Typ 2, Fettleibigkeit und/oder Herz-Kreislauf-Erkrankungen, sowie Erkrankungen, die durch T-Zellen verursacht sind, bzw. die durch Beeinflussung von T-Zellen behandelbar sind, und insbesondere durch Hemmung von DPP4 bzw. dessen zellgebundener Form CD26 und/oder APN und/oder zAAP behandelbar sind, z.B. Autoimmunerkrankungen. Weiterhin betrifft die Erfindung pharmazeutische Zusammensetzungen zur Verwendung bei neuronalen Erkrankungen, die durch Hemmung der DPP4 bzw. von CD26 und/oder Hemmung von APN und/oder zAAP und/oder bei neuronalen Erkrankungen, durch Hemmung der DPP 8 und/oder DPP9 behandelbar sind.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008062136A DE102008062136B4 (de) | 2008-12-16 | 2008-12-16 | Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch |
DE102008062136.6 | 2008-12-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010072327A2 WO2010072327A2 (de) | 2010-07-01 |
WO2010072327A3 true WO2010072327A3 (de) | 2010-12-29 |
Family
ID=42168685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/008768 WO2010072327A2 (de) | 2008-12-16 | 2009-12-08 | Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102008062136B4 (de) |
WO (1) | WO2010072327A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150018566A1 (en) | 2011-08-25 | 2015-01-15 | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy | Tubulin binding agents |
EP2824110A4 (de) * | 2012-03-09 | 2015-12-30 | Morinaga Milk Industry Co Ltd | Dipeptidylpeptidase-iv-hemmer |
JP6517732B2 (ja) * | 2016-06-01 | 2019-05-22 | 株式会社ニッピ | Dpp−4阻害剤、血糖値上昇抑制剤およびdpp−4阻害用食品 |
US10336817B2 (en) | 2016-10-14 | 2019-07-02 | Sultan Qaboos University | Therapeutic composition of camel milk |
CN109645123A (zh) * | 2018-11-06 | 2019-04-19 | 新疆金驼投资股份有限公司 | 一种具有调节脂代谢功能的益生菌jt6骆驼乳粉组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003729A1 (de) * | 1998-07-15 | 2000-01-27 | Ursapharm Arzneimittel Gmbh | Verwendung von bromelainproteasen zur hemmung der blutgerinnung |
WO2000014254A2 (en) * | 1998-09-02 | 2000-03-16 | Cortecs (Uk) Limited | Component of bromelain |
WO2006068480A2 (en) * | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
JP2007039424A (ja) * | 2005-07-01 | 2007-02-15 | Snow Brand Milk Prod Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
DE102004040452A1 (de) * | 2004-08-20 | 2006-02-23 | N.V. Nutricia | Peptidgemisch |
US7219998B2 (en) * | 2004-12-16 | 2007-05-22 | Bausch And Lomb Incorporated | Dot radial ringed placido |
-
2008
- 2008-12-16 DE DE102008062136A patent/DE102008062136B4/de active Active
-
2009
- 2009-12-08 WO PCT/EP2009/008768 patent/WO2010072327A2/de active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003729A1 (de) * | 1998-07-15 | 2000-01-27 | Ursapharm Arzneimittel Gmbh | Verwendung von bromelainproteasen zur hemmung der blutgerinnung |
WO2000014254A2 (en) * | 1998-09-02 | 2000-03-16 | Cortecs (Uk) Limited | Component of bromelain |
WO2006068480A2 (en) * | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
JP2007039424A (ja) * | 2005-07-01 | 2007-02-15 | Snow Brand Milk Prod Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 200722, Derwent World Patents Index; AN 2007-214433, XP002597235, SNOW BRAND MILK PROD CO LTD: "Dipeptidyl peptidase IV inhibitor useful for treating obesity, non-insulin dependent diabetes mellitus and hyperglycemia, comprises water-soluble fraction of cheese as active ingredient" * |
KOHMURA M ET AL: "INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME BY SYNTHETIC PEPTIDES OF HUMAN BETA-CASEIN", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM, TOKYO, JP, vol. 53, no. 8, 1 August 1989 (1989-08-01), pages 2107 - 2114, XP001105965, ISSN: 0002-1369 * |
Also Published As
Publication number | Publication date |
---|---|
DE102008062136A1 (de) | 2010-06-17 |
DE102008062136B4 (de) | 2012-05-03 |
WO2010072327A2 (de) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009130198A3 (en) | Hyperglycosylated human coagulation factor ix | |
GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
WO2007044591A3 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
IL184554A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
WO2008070692A8 (en) | Bicyclic compounds and use as antidiabetics | |
CL2008001125A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
CL2008001126A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
WO2011059763A3 (en) | Dimeric smac mimetics | |
WO2007009894A3 (en) | Peptides for use in the treatment of obesity | |
WO2012080727A3 (en) | Casein kinase 1delta (ck1delta) inhibitors | |
WO2011150156A3 (en) | Heteroaryl compounds and methods of use thereof | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
WO2007007173A3 (en) | Human anti-madcam antibodies | |
UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
WO2006042152A3 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
WO2011011797A3 (en) | Cytokine compositions and methods of use thereof | |
WO2010072327A3 (de) | Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch | |
WO2008087186A3 (en) | Peptides for use in the treatment of obesity | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
WO2010085700A3 (en) | Treatment for obesity | |
PL2083809T3 (pl) | Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji | |
WO2008087188A3 (en) | Peptides for use in the treatment of obesity | |
WO2009008913A3 (en) | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 112(1) EPUE (EPA FORM 1205A VOM 31/08/2011) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09767985 Country of ref document: EP Kind code of ref document: A2 |